Futures dipped. Tesla earnings headlined overnight action. Former President Trump is taking a new social media firm public.
Wall Street has known its share of legends, but few of them have made as big a splash as “the Man Who Broke the Bank of England.” That nickname belongs to George Soros who earned the tag after famously betting against the British Pound in 1992; following the Black Wednesday crash, the hedge fund manager pocketed $1 billion in a single day. This is the stuff that Wall Street legends are made of. By then Soros was already incredibly successful and in the midst of steering his Quantum Fund to decad
The professor is known for being bullish on stocks, yet even he says trouble’s coming.
Don't forget about Novavax (NASDAQ: NVAX). Here's why Novavax stock could skyrocket in December. In this case, there could be increased demand for vaccines that are effective against the omicron variant.
Satya Nadella sold 838,584 shares between Nov. 23 and Nov. 24. The move comes a month before Washington state's capital gains tax goes into effect.
Creating reliable streams of retirement income is one of the most important elements of a person’s financial plan. A retirement industry giant says it now has a new way for retirees to meet this vital challenge. Fidelity Investments plans to … Continue reading → The post There’s a New Way to Convert Your 401(k) into a Pension-like Stream of Income appeared first on SmartAsset Blog.
On Nov. 15, institutional investors and hedge funds with at least $100 million in assets under management were required to file Form 13F with the Securities and Exchange Commission (SEC). With the latest round of 13Fs, one thing stands out: billionaires were buying stocks hand over fist. Billionaire Ken Griffin is a wildly successful investor who's known for extracting big wins from his firms' options positions.
Scotiabank reported net income of $9,955 million for the fiscal year 2021, compared with net income of $6,853 million in 2020. Diluted earnings per share (EPS) were $7.70, compared to $5.30 in the previous year. Return on equity was 14.7%, compared to 10.4% in the previous year.
(Bloomberg) -- Fresh concerns about the efficacy of existing vaccines against the omicron coronavirus strain pushed markets back into risk-off mode on Tuesday, with U.S. equity futures dropping along with stocks in Europe. Bonds gained as investors sought havens.Most Read from BloombergChina Cash Flowed Through Congo Bank to Former President’s Cronies‘Pension Poachers’ Are Targeting America’s Elderly VeteransReliving the New York Subway Map DebateS&P 500 contracts slid about 1% and the U.S. 10-y
Shares of biopharma company Vir Biotechnology (NASDAQ: VIR) are up 13.7% as of 11:57 a.m. ET on Monday in response to reports that a new strain of the COVID-19 virus has been identified. Indeed, headlines regarding the new omicron variant of the coronavirus began to surface before Thursday's Thanksgiving holiday. It just took a while for investors to connect the dots all the way back to Vir Biotechnology, which potentially benefits from a renewed outbreak of infections stemming from this new strain of the pandemic-causing virus.
Moderna CEO Stephane Bancel predicts a 'material drop' in the effectiveness of current vaccines against the Omicron variant.
Growth in its core Chinese e-commerce division, as well as in cloud computing and its international business, are likely to be crucial to Alibaba's stock.
Dow Jones futures dived 400 points early Tuesday, as the Moderna CEO predicted existing vaccines will be less effective for omicron.
U.S. legalization is still stalled, but Mexican marijuana legalization could be imminent.
After sliding along with the rest of the stock market on Friday, shares of lithium mining stock Lithium Americas (NYSE: LAC) are rebounding in a big way on Monday -- up 13.6% as of 12:15 p.m. ET. You can thank the friendly analysts at National Bank Financial for that. No sooner had Lithium Americas finished its Friday slide than an analyst at the Canadian investment bank stepped in and reiterated an outperform recommendation on the stock.
A new analysis compared the Radnor firm's potential treatment to other therapies now being used to treat Covid-19.
The current year is winding down, and investors are starting to prepare for 2022. They’ll shed the non-performers from their portfolios, double down on the winners, and scan the markets to find stocks that are ready to pop. It’s the usual merry-go-round game of the market, just with a New Years’ theme. In this sort of environment, it’s no wonder to find investors drawn to the top-rated stocks. These are the Street’s Strong Buy-rated equities, the stocks that have picked up a deeply positive cons
The variant’s emergence in South Africa has driven a sharp increase in hospitalizations in Gauteng province during the past two weeks, although fewer patients than in previous surges are being treated for severe disease.
The CEO of Moderna told the Financial Times there's no world where current vaccines are as effective as against the delta variant.
Words have power -- as investors discovered to their dismay last week. News of the new omicron variant of COVID-19 shocked the stock market, sending shares of cruise line stocks Royal Caribbean (NYSE: RCL), Carnival (NYSE: CCL) (NYSE: CUK), and Norwegian Cruise Line Holdings (NYSE: NCLH) tumbling 10% and more in Friday trading.
Yahoo Finance's Ines Ferre provides an update on Merck, Tesla, and Avis stocks.